Bjerre

About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 126 blog entries.

KalVista Pharmaceuticals Provides Operational Update

2017-07-28T07:14:34+00:00

KalVista Pharmaceuticals, Inc. provides an operational update and released financial results for the fiscal fourth quarter and full year ended 30 April 2017. From CEO Andrew Crockett's remarks: "KalVista has been making substantial advances with our portfolio of oral small molecule plasma kallikrein inhibitors for treatment of HAE. The first HAE program in the portfolio, KVD818, [...]

Pharming Reports on Financial Results for the First Half of 2017

2017-07-27T16:38:29+00:00

Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2017. CEO Sijmen de Vries comments: "Our strategic decision to reacquire the commercial rights to sell RUCONEST in North America has significantly increased revenue and profit generation for the first half of the year compared to the first half of [...]

The Lancet publicizes RUCONEST® prophylactic data

2017-07-26T17:41:20+00:00

The weekly peer-reviewed general medical journal The Lancet has published data from a Phase II, double-blind, placebo-controlled, randomized clinical trial (NCT02247739) evaluating the efficacy and safety of RUCONEST (C1 esterase inhibitor [recombinant]) for the prevention of HAE attacks. As previously reported, in a study with 32 patients RUCONEST® 50 IU/kg (max 4200 IU) demonstrated a [...]

FDA Orphan-Drug Exclusivity for HAEGARDA

2017-07-22T03:26:39+00:00

The U.S. Food and Drug Administration (FDA) has granted CSL Behring seven years of orphan-drug exclusivity for HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous treatment option for prevention of HAE attacks. HAEGARDA was approved by the FDA on 22 June 2017 for routine prophylaxis to prevent HAE attacks in adolescent and [...]

Second 2017 edition of “Global Perspectives” out now

2017-07-01T05:24:51+00:00

We are excited to inform you that the second 2017 edition of “Global Perspectives” – the HAEi magazine – is out today. Among many other topics you will find: the story of Patricia Karani, the new HAEi Regional Patient Advocate for Sub-Sahara Africa highlights from the 10th C1-INH workshop in Budapest, Hungary news from our Regional Patient [...]

Regional Patient Advocate for sub-Sahara Africa

2017-06-27T00:11:33+00:00

Early 2016 HAEi appointed five Regional Patient Advocates, dividing a large portion of the world between them. As per 1 July 2017, they are joined by Patricia Karani who will be focusing on the sub-Sahara part of the African continent. Patricia Karani was born in Nairobi, Kenya where she is currently residing. She holds a [...]

FDA approves first subcutaneous C1 Esterase Inhibitor

2017-06-23T16:08:51+00:00

The U.S. Food and Drug Administration has approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent HAE attacks in adolescent and adult patients. The subcutaneous route of administration allows for easier at-home self-injection by the patient or caregiver, once proper training is received. "The approval of Haegarda provides [...]

Thousands helped raise HAE awareness step by step

2017-06-02T01:00:08+00:00

On and around hae day :-) 2017 a group of HAE patients, caregivers, doctors and people from HAE organizations walked four stages of the Camino in northern Spain. Many more would have liked to take part in this walk but were not able to do so. Therefore HAEi arranged the HAE Global Walk 2017, allowing [...]

Positive Results From the Second Interim Analysis

2017-05-31T19:25:10+00:00

BioCryst Pharmaceuticals, Inc. has announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in HAE. APeX-1 is a 3-part dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered once-daily (QD) BCX7353 for 28 days, as a preventative treatment to reduce the frequency of [...]